Levetiracetam in tardive dyskinesia: an open label study

Movement Disorders : Official Journal of the Movement Disorder Society
Spiros KonitsiotisVenos Mavreas

Abstract

Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia were evaluated in an open label study. Eight patients received oral LEV (1,000 mg/day) for 1 month and blinded evaluations were performed at baseline and at the end of the treatment period. A significant reduction of the abnormal movements was recorded while psychiatric symptoms did not worsen and the adverse event profile was benign. LEV may be efficacious for the treatment of tardive dyskinesia and deserves further clinical testing.

References

Mar 18, 2000·Pharmacology & Therapeutics·P N Patsalos
Mar 29, 2001·Journal of Clinical Psychopharmacology·C FehrA Szegedi
Feb 5, 2003·Seizure : the Journal of the British Epilepsy Association·Henrik KlitgaardDoru-Georg Margineanu
Aug 13, 2003·Neurology·Cameron L McGavinWilliam S Musser
Feb 6, 2004·European Journal of Pharmacology·Erwan BezardHenrik Klitgaard
Aug 21, 2004·Clinical Neuropharmacology·Michael P HillHenrik Klitgaard
Mar 30, 2005·Clinical Neuropharmacology·G MecoL Morgante
Jun 15, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Theresa A ZesiewiczRobert A Hauser

❮ Previous
Next ❯

Citations

Apr 27, 2011·Current Psychiatry Reports·Vladimir Lerner, Chanoch Miodownik
Jun 4, 2008·Clinical Neuropharmacology·Pietro Biagio CarrieriSilvana Montella
Nov 16, 2013·Drug Design, Development and Therapy·Abdul Qayyum RanaPierre J Blanchet
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Leslie J CloudStewart A Factor
Nov 13, 2014·Neurology India·Ajish MangotVaibhav Dubey
Mar 3, 2011·Journal of Clinical Psychopharmacology·Yesim Yetimalar BeckmannYeliz Çiftçi
Jul 15, 2015·Expert Opinion on Emerging Drugs·Jonathan Tomas Lockwood, Gary Remington
Apr 19, 2011·Epilepsy & Behavior : E&B·Kenneth R Kaufman
Jan 29, 2008·Journal of Clinical Pharmacology·Christopher KenneyJoseph Jankovic
Nov 13, 2007·Acta Neurologica Scandinavica·S A ZivkovićK M Abu-Elmagd
Mar 18, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·P StathisUNKNOWN VALID-PD Study Group
Jan 6, 2015·Psychiatry and Clinical Neurosciences·Paul P LernerVladimir Lerner
Apr 27, 2017·Expert Opinion on Pharmacotherapy·Daniel P WitterUma Suryadevara
Jun 9, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Sascha HeringJoerg Mueller
Mar 7, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Muhammad U FarooqMounzer Y Kassab
Jun 4, 2010·Journal of Clinical Psychopharmacology·Pao-Huan Chen, Hsing-Cheng Liu
Oct 5, 2013·Continuum : Lifelong Learning in Neurology·Ruth H Walker
Jul 29, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stewart A Factor
Sep 1, 2007·Clinical Neuropharmacology·Murat AlemdarSezer Sener Komsuoğlu
Apr 14, 2020·Neurologic Clinics·Hassaan H Bashir, Joseph Jankovic

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.